Study to Assess the Safety and Efficacy of Tenapanor for the Treatment of IBS-C
Status:
Recruiting
Trial end date:
2024-10-31
Target enrollment:
Participant gender:
Summary
This is a randomized, double-blind, placebo-controlled study to assess the efficacy, safety
and tolerability of tenapanor (25 mg and 50 mg) in pediatric patients (≥12 and <18 years old)
with IBS-C when administered twice daily (BID) for 12 consecutive weeks.